Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | DRD5 | P21918 | 2/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18976755 | 0.89 | DRD2 (0.39) | HTR7DRD2DRD3DRD1DRD4 | |
| SCHEMBL38666603 | 0.86 | BCHE (0.52) | HTR7 | |
| SCHEMBL24662792 | 0.85 | HTR7 (0.43) | HTR7DRD2DRD3 | |
| SCHEMBL17778508 | 0.85 | HTR7 (0.43) | HTR7DRD2DRD3 | |
| SCHEMBL13548816 | 0.85 | HTR7 (0.43) | HTR7DRD2DRD3 | |
| SCHEMBL6784201 | 0.83 | DRD2 (0.47) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL27015307 | 0.80 | DRD4 (0.45) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL18963853 | 0.80 | GBA1 (0.38) | HTR7DRD2DRD3DRD1DRD4 | |
| SCHEMBL22624219 | 0.78 | KMT2A (0.40) | HTR7KDM2B | |
| SCHEMBL16219825 | 0.78 | HTR7 (0.41) | HTR7DRD2DRD3DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975250-B2 | 5 oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as CaMKII kinase inhibitors for treating cardiovascular diseases | SANOFI (FR) | 2015-03-10 | — | — | US | disclosed |
| EP-2706059-A1 | Diazacarbazoles and methods of use | Genentech, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20120277220-A1 | 5 OXO-5,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI (FR) | 2012-11-01 | — | — | US | disclosed |
| WO-2011086306-A9 | 5-OXO-5, 8-DIHYDROPYRIDO [2, 3-D] PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI-AVENTIS (FR) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011086306-A1 | 5-OXO-5, 8-DIHYDROPYRIDO [2, 3-D] PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | HTR7 3929/4885DRD2 4839/4885DRD3 4785/4885 |
| US-20120277220-A1 | 5 OXO-5,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | CAMKK1, CAMKK2, CAMK1 | HTR7 2192/4885DRD2 1880/4885DRD3 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.